• Publications
  • Influence
Physical activity in patients with COPD
Physical activity is reduced in patients with chronic obstructive pulmonary disease from Global Initiative for Chronic Obstructive Lung Disease stage II/ body mass index, airway obstruction, dyspnoea, exercise capacity score 1.
Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocORTicoid therapy, but there was a greater decrease in lung function during the final step of glucoc Corticoid withdrawal.
Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction
The International Olympic Committee Medical Commission (IOC-MC) requires notification for use of a β2 agonist at the Winter Olympic Games in Salt Lake City and must be accompanied by objective evidence that justifies the need to use one.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD
Results show that the use of tiotropium was associated with sustained reductions of lung hyperinflation at rest and during exercise and contributed to improvements in both exertional dyspnoea and exercise endurance.
The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity.
Almost one-half of the patients with CB/COPD had coexisting metabolic syndrome, with a slightly lower frequency in patients with severe COPD, which is associated with an increase in the levels of some systemic inflammatory markers and physical inactivity, independent of lung function impairment.
An official European Respiratory Society statement on physical activity in COPD
This European Respiratory Society (ERS) statement provides a comprehensive overview on physical activity in patients with chronic obstructive pulmonary disease (COPD). A multidisciplinary Task Force
Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study.
Higher values of systemic inflammation and left cardiac dysfunction are associated with reduced physical activity in patients with COPD.
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
Once-daily indacaterol is an effective 24’h bronchodilator that improves symptoms and health status and confers clinical improvements over a twice-daily 12 h LABA as a treatment for patients with moderate to severe COPD.
Pulmonary biomarkers in chronic obstructive pulmonary disease.
Pulmonary biomarkers may be useful in predicting disease progression, indicating disease instability, and in predicting response to current therapies and novel therapies, many of which are now in development.